Table 3.
Risk of All Cause Mortality Based on Clinical Factors at Random Assignment and at the Time of PSA Recurrence (N = 206)
| Clinical Factor | Unadjusted HR | 95% CI | P | Adjusted HR | 95% CI | P |
|---|---|---|---|---|---|---|
| Age, years (at random assignment, continuous) | 1.07 | 1.02 to 1.13 | .006 | 1.06 | 1.003 to 1.11 | .04 |
| Treatment arm | ||||||
| RT and AST | 1.00 | — | 1.00 | — | ||
| RT alone | 1.62 | 1.02 to 2.58 | .04 | 2.37 | 1.18 to 4.76 | .02 |
| Log PSA | 1.31 | 0.92 to 1.86 | .132 | 1.12 | 0.80 to 1.57 | .51 |
| Gleason score | ||||||
| ≤ 6 | 1.00 | — | 1.00 | — | ||
| 7 | 1.23 | 0.70 to 2.18 | .48 | 0.80 | 0.43 to 1.49 | .48 |
| 8-10 | 2.90 | 1.49 to 5.65 | .002 | 1.52 | 0.74 to 3.13 | .25 |
| Tumor category | ||||||
| T1 | 1.00 | — | 1.00 | — | ||
| T2 | 1.47 | 0.92 to 2.34 | .11 | 0.98 | 0.59 to 1.62 | .94 |
| ACE-27 comorbidity score | ||||||
| No or minimal | 1.00 | — | 1.00 | — | ||
| Moderate to severe | 3.53 | 2.22 to 5.61 | < .001 | 12.73 | 5.91 to 27.41 | < .001 |
| Treatment arm comorbidity* | 0.15 | 0.06 to 0.40 | < .001 | 0.17 | 0.06 to 0.48 | < .001 |
| Time-dependent PSA velocity | 1.59 | 1.38 to 1.82 | < .001 | 1.47 | 1.24 to 1.75 | < .001 |
| Time-dependent salvage AST | 1.38 | 1.22 to 1.56 | < .001 | 1.24 | 1.07 to 1.44 | .004 |
Abbreviations: PSA, prostate-specific antigen; HR, hazard ratio; RT, radiation therapy; AST, androgen suppression therapy; ACE-27, Adult Comorbidity Evaluation 27.
*
Interaction term.